Elorac, Inc.
Industry
- Pharmaceuticals
- Specialty Pharmaceuticals
See more in Biomedtracker
Latest on Elorac, Inc.
Scrip
• By John Davis
Top-line results from KALM-2, the second of two Phase III studies of Cara Therapeutics Inc. 's pruritus therapy, Korsuva (CR845/difelikefalin), have confirmed the efficacy of the intravenous therapy
Scrip
• By Jessica Merrill
The first positive Phase III data from AbbVie Inc. and partner Neurocrine Biosciences Inc. for elagolix for the treatment of heavy menstrual bleeding in women with uterine fibroids puts pressu